BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Policy

  CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review

  If approved, etranacogene dezaparvovec would be the first gene therapy treatment for hemophilia B.

  May 24, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Ocugen Unveils New Phase III Cell Therapy Platform

  Ocugen introduced NeoCart, which is designed to repair full-thickness lesions of the knee cartilage in adults, as a Phase III cell therapy platform technology.

  May 24, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Supply Chain Issues Hamper Caladrius’ Cardiovascular Study

  Caladrius Biosciences announced it was suspending enrollment in its Phase IIb FREEDOM study assessing xowna for coronary microvascular dysfunction (CMD) due to supply chain issues.

  May 24, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Alnylam Adds More Evidence for Lumasiran to Successful Week

  Alnylam Pharmaceuticals announced Tuesday new positive results from the Phase III ILLUMINATE-C trial of lumasiran for advanced primary hyperoxaluria type 1 (PH1).

  May 24, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  Following Disappointing Trial and Assessment, Genocea Shutters its Doors

  Genocea’s board of directors voted to wind down ongoing operations and terminate its remaining staff, except for those necessary to see the company’s closing.

  May 24, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Employer Resources

  BioSpace Introduces Diversity in Life Sciences Content Series

  This summer, BioSpace will release a series of reports looking at the current state of diversity and inclusion in the life sciences.

  May 24, 2022

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Pfizer and Lilly Zero in on Success in Ulcerative Colitis

  Pfizer and Eli Lilly are forging ahead with ulcerative colitis (UC) research after posting positive results from their respective Phase III studies.

  May 24, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Inaugural Patient Injected with Cancer-Killing Oncolytic Virus

  Imugene and City of Hope announced that the first patient has begun treatment in a Phase I clinical trial, investigating the safety and efficacy of CF33-hNIS in adults with metastatic or advanced tumors.

  May 24, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  New Report Highlights Potential of Largely Untapped Drug Development Target

  A new report in La Merie Publishing describes and analyzes cadherin 17 as a promising target for drug development, which has largely gone unexploited.

  May 24, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  KaliVir’s Oncolytic Virus Platform Bags Another Big Fish in Roche

  Two months after closing its Series A financing round, KaliVir Immunotherapeutics forged an exclusive licensing and collaboration agreement with Roche.

  May 24, 2022

   · 

  2 min read

   · 

  Alex Keown